The Human Capital Reckoning: How GLP-1s, Mental Health Mandates, and AI Are Rewriting Healthcare Economics
The global healthcare and wellness ecosystem is undergoing a structural overhaul driven by GLP-1 adoption, institutional...
Read More →The global healthcare and wellness ecosystem is undergoing a structural overhaul driven by GLP-1 adoption, institutional...
Read More →The 2026 U.S. healthcare sector faces a structural realignment driven by aggressive FTC antitrust enforcement, the explo...
Read More →Washington has pulled healthcare's pricing, research and immunization levers in a single fortnight, from the August 10 c...
Read More →Three unrelated policy and capital events — the first FDA-approved mRNA flu vaccine, the Medicare GLP-1 Bridge program...
Read More →WADA's 2026 monitoring list and new biological aging data reveal how GLP-1s are fundamentally altering the economics of ...
Read More →Driven by FTC antitrust probes into PBMs and sweeping HIPAA security overhauls, the U.S. healthcare system is undergoing...
Read More →Major health insurers are entrenching margin-first operational blueprints as the Provider Reimbursement Stability Act ad...
Read More →The 2026 convergence of a 70-million-consumer exodus, the explosion of the authenticated resale market, and the geopolit...
Read More →The 2026 convergence of LVMH’s fragile recovery, a $41.61 billion secondary market boom, and unprecedented retail real...
Read More →The FDA has officially permitted the use of bemotrizinol in U.S. sunscreens starting August 9, 2026, marking the first n...
Read More →The FDA has approved Takeda's Orzeyful (oveporexton), the first-in-class orexin receptor agonist designed to treat the u...
Read More →In a sweeping policy shift, the DOJ has signaled it will no longer enforce the landmark Olmstead decision, while Medicai...
Read More →